I am a breastfeeding mother and i want to know if it is safe to use 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol? Is 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol safe for nursing mother and child? Does 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol extracts into breast milk? Does 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol has any long term or short term side effects on infants? Can 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol influence milk supply or can 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol decrease milk supply in lactating mothers?
- DrLact safety Score for 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
On last update relevant published data concerning breastfeeding were not found. Pharmacokinetic data suggest that excretion into breast milk would be significant. However, it is considered safe for treatment of parasite infections like Amebiasis in children, with a dosage for children weighing over 5 kg that has been established by the manufacturer. It is a medication included in a same group and similar properties of Metronidazole.
No information is available on the clinical use of 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol during breastfeeding and no studies have evaluated adverse effects of 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol on the infant during breastfeeding, but presumably they are similar to those of the closely related drug, metronidazole, such as increased risk of oral and rectal infections. As with metronidazole, concern has been raised about exposure of healthy infants to 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol via breastmilk, because of possible mutagenicity and carcinogenicity. Based on the 1-(2-Methyl-5-nitro-1-imidazolyl)-2-propanol's elimination half-life of approximately 17 hours, the manufacturer recommends avoidance of breastfeeding for 96 after a single dose. Other drugs are available for bacterial vaginosis, and can be given vaginally, which should result in lower amounts in breastmilk.
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.